CVS Health (CVS) PT Raised to $102 at Truist Securities, remains bullish
Truist Securities analyst David MacDonald raised the price target on CVS Health (NYSE: CVS) to $102.00 (from $98.00) while maintaining a Buy rating.
The analyst commented: "We remain bullish on CVS on the heels of strong 1Q results and raised FY26 guidance with HCB margin improvement the key driver. MA commentary was constructive while P&CW trends were solid and Health Services results reflect improved delivery growth driven by Oak Street. We expect the coming consumer engagement rollout to further improve connectivity, and we continue to like CVS’ positioning given its broad/differentiated collection of assets. CF was also ahead with guidance raised and improved leverage"